Literature DB >> 6321197

Functionally inactive apolipoprotein E3 in a type III hyperlipoproteinaemic patient.

L M Havekes, J A Gevers Leuven, E van Corven, E de Wit, J J Emeis.   

Abstract

Type III hyperlipoproteinaemia (HLP) is, amongst others, characterized by the E2/2 phenotype as determined by isoelectric focusing of apolipoprotein E. However, one of our clinically symptomatic type III HLP patients showed a E3/3 phenotype. After complexation with phospholipid vesicles, apo E from this patient was, in contrast with apo E from a type IV HLP patient (E3/4 phenotype), unable to compete with low density lipoprotein (LDL) for binding to the specific LDL receptors on cultured human fibroblasts. This defect in binding to the LDL receptor was not due to an impaired lipid binding capability. The clinical symptomatic type III hyperlipoproteinaemia of our patient is probably due to a functionally inactive apo E3.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6321197     DOI: 10.1111/j.1365-2362.1984.tb00696.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Apolipoprotein E phenotypes and hyperlipidemia.

Authors:  G Utermann; I Kindermann; H Kaffarnik; A Steinmetz
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

2.  Pre-beta-very low density lipoproteins as precursors of beta-very low density lipoproteins. A model for the pathogenesis of familial dysbetalipoproteinemia (type III hyperlipoproteinemia).

Authors:  D A Chappell
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

3.  Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.

Authors:  P de Knijff; A M van den Maagdenberg; D I Boomsma; A F Stalenhoef; A H Smelt; J J Kastelein; A D Marais; R R Frants; L M Havekes
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

4.  Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.

Authors:  P de Knijff; A M van den Maagdenberg; A F Stalenhoef; J A Leuven; P N Demacker; L P Kuyt; R R Frants; L M Havekes
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

5.  Familial disorders of plasma apolipoproteins.

Authors:  C R Sirtori; G Franceschini
Journal:  Klin Wochenschr       Date:  1985-06-03

6.  Apolipoprotein E3-Leiden. A new variant of human apolipoprotein E associated with familial type III hyperlipoproteinemia.

Authors:  L Havekes; E de Wit; J G Leuven; E Klasen; G Utermann; W Weber; U Beisiegel
Journal:  Hum Genet       Date:  1986-06       Impact factor: 4.132

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.